<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Respiratory Syncytial Virus Infection Pathway" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Infection with human respiratory syncytial virus (hRSV) is transmitted through close contact, fomites, and aerosolized droplets. RSV first infects the epithelial lining of the upper respiratory tract and nasopharynx where the virus begins to replicate, and from there it may spread to the lower respiratory tract - bronchioles and alveoli - especially in infants. Immune response to RSV infection increases mucus production which, in combination with inflammation, leads to the narrowing of airways and bronchiolitis. Experimental vaccination with a formalin-inactivated RSV has been associated with vaccine-enhanced disease, which has hindered vaccine development and led to advancement of costly and modestly effective therapies based on monoclonal antibodies (mAb) and small molecules, which act to block RSV entry and have been reserved for high-risk patients (reviewed in Battles and McLellan 2019, and Pandya et al. 2019). Recently, a prophylactic mAb Nirsevimab was approved for use in all infants (reviewed in Keam 2023). Some of the preF vaccines, which elicit immune response against the pre-fusion conformation of the F protein (pre-F), are in the late stages of clinical trial or undergoing approval for being used in elderly patients and pregnant women (reviewed in Jenkins et al. 2023).&lt;br&gt;&lt;br&gt;RSV is classified into two distinct subtypes, RSV A and RSV B, predominantly based on antigenic and sequence-based variations in the viral envelope protein G, involved in virus attachment to the host cells. Multiple RSV genotypes are often in co-circulation with a dominance shift between RSV A and RSV B subtypes occurring every 1-2 years. The majority of RSV molecular studies use a limited number of historical isolates, the so-called laboratory strains, of which hRSV A substrain A2 is the most commonly used. If not indicated otherwise, the events described in this pathway refer to findings from hRSV A2-based studies.&lt;br&gt;&lt;br&gt;For review, please refer to Battles and McLellan 2019, and Pandya et al. 2019.
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=9820952 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 9820952</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Orlic-Milacic, Marija</Comment>
  <BiopaxRef>d9d</BiopaxRef>
  <BiopaxRef>df7</BiopaxRef>
  <BiopaxRef>cbd</BiopaxRef>
  <BiopaxRef>ac8</BiopaxRef>
  <Attribute Key="reactome_id" Value="9820952" />
  <Graphics BoardWidth="692.0" BoardHeight="326.0" />
  <DataNode TextLabel="Respiratory&#xA;syncytial virus&#xA;(RSV) genome&#xA;replication,&#xA;transcription and&#xA;translation" GraphId="aa86f" Type="Pathway">
    <Comment Source="Reactome">After the human respiratory syncytial virus A (hRSV A) enters host cells, an initial round of transcription and translation of virally-encoded mRNAs ensues, which is followed by genome replication.&lt;br&gt;&lt;br&gt;The negative sense, single-stranded RNA (-ssRNA) genome of the human respiratory syncytial virus (RSV) A is 15.2 kb long and contains 10 genes that encode 11 proteins. The 10 genes, going from the 3' end to the 5' end of the -ssRNA are: 1C (NS1), 1B (NS2), N, P, M, SH, G, F, M2, and L. Except for the M2 gene, each gene encodes one protein. The two overlapping open reading frames (ORFs) of the M2 gene encode proteins M2-1 and M2-2.&lt;br&gt;&lt;br&gt;The N gene encodes the nucleoprotein, which forms decameric and hendecameric (11-fold) rings around which viral genomic RNA is packaged. The L and P genes encode the large polymerase subunit and the phosphoprotein polymerase cofactor subunit, respectively, of the RNA-dependent RNA polymerase complex (RdRP) (reviewed in Battles and McLellan 2019). The L protein contains three conserved enzymatic domains: the RNA-dependent RNA polymerase (RdRp) domain, the polyribonucleotidyl transferase (PRNTase or capping) domain, and the methyltransferase (MTase) domain (reviewed in Sutto-Ortiz et al. 2023). The M2-1 product of the M2 gene is a transcription processivity factor, while the M2-2 product of the M2 gene is a nonstructural protein that regulates the switch between transcription and genome replication. The SH, G, and F genes encode three proteins that are embedded in the viral envelope: small hydrophobic protein, attachment protein, and fusion protein, respectively. The secreted isoform of G protein (sG) mediates immune evasion. The NS1 and NS2 genes encode nonstructural proteins that function together to inhibit apoptosis and interferon response in infected cells. For review, please refer to Battles and McLellan 2019.&lt;br&gt;&lt;br&gt;The genomic -ssRNA and the antigenome RNA are encapsidated as they are synthesized, and the association of the nascent RNA with the N protein is likely what causes the replicating polymerase to be processive, with the processivity being further augmented by the M2-1 processivity factor (reviewed in Fearns and Deval 2016). The C-terminal arm of the N protein, known to interact with the P protein subunit of RdRP complex, extends above the plane of N decamers. The interaction between N and P proteins may allow the RdRP complex to distort the helical conformation of the nucleocapsid during RNA synthesis. A long beta-hairpin in the N-terminal region of the N protein may be the site of contact with the catalytic L subunit of the RdRP complex. The proposed model for RNA synthesis in RSV is that the RdRP complex induces a hinge movement of the N-terminal region with respect to the C-terminal region of the N protein that allows the polymerase to thread through the template RNA without the need to disassemble the nucleocapsid (Tawar et al. 2009). The hinge movement would enable 11 bases available for readout at a time (Tawar et al. 2009), consistent with the accumulation of abortive transcripts 9-11 nucleotides in length in P protein phosphorylation mutants that impair transcript elongation (Dupuy et al. 1999).&lt;br&gt;&lt;br&gt;The M2-2 protein regulates the shift from positive to negative sense RNA synthesis. While the mechanism has not been fully elucidated, M2-2 was shown to directly bind to the L protein and to inhibit positive sense RNA synthesis (reviewed in Noton and Fearns 2015).&lt;br&gt;&lt;br&gt;For review, please refer to Collins et al. 2013. </Comment>
    <BiopaxRef>d9d</BiopaxRef>
    <BiopaxRef>d69</BiopaxRef>
    <BiopaxRef>ce8</BiopaxRef>
    <BiopaxRef>b75</BiopaxRef>
    <BiopaxRef>f4a</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="411.5" CenterY="145.0" Width="497.0" Height="52.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9820965" />
  </DataNode>
  <DataNode TextLabel="Respiratory&#xA;syncytial virus&#xA;(RSV) attachment&#xA;and entry" GraphId="c5f41" Type="Pathway">
    <Comment Source="Reactome">The entry of human respiratory syncytial virus (RSV) into host cells involves attachment of the virion to the host cell surface, through interaction of viral envelope proteins with host cell attachment factors, and fusion of the viral membrane with the host cell membrane. The G glycoprotein is the attachment protein that interacts with surface molecules of the host cells, enabling the RSV virions to bind to their target cells. While the F glycoprotein may facilitate attachment, its primary function is to promote fusion of the viral and host cell membranes. The SH protein is dispensable for entry. For review, please refer to Battles and McLellan 2019.&lt;br&gt;&lt;br&gt;Using human primary airway epithelial cell cultures, it was established that RSV efficiently infects the airway epithelium from the luminal surface and specifically targets ciliated airway epithelial cells. In the absence of immune response, RSV causes no obvious cytopathology (Zhang et al. 2002).&lt;br&gt;&lt;br&gt;In addition to ciliated respiratory epithelial cells, RSV may infect granulocytes and cause a delay in constitutive apoptosis of neutrophils and eosinophils (Lindemans et al. 2006). RSV can also infect neonatal-specific regulatory B cells, which may contribute to high viral load and disease severity in infants (Zhivaki et al. 2017).</Comment>
    <BiopaxRef>d9d</BiopaxRef>
    <BiopaxRef>c95</BiopaxRef>
    <BiopaxRef>ada</BiopaxRef>
    <BiopaxRef>a9b</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="411.0" CenterY="80.0" Width="494.0" Height="50.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9820960" />
  </DataNode>
  <DataNode TextLabel="Assembly and release&#xA;of respiratory&#xA;syncytial virus&#xA;(RSV) virions" GraphId="cfe06" Type="Pathway">
    <Comment Source="Reactome">A mature virion of the respiratory syncytial virus (RSV) consists of the ribonucleoprotein complex (RNP) surrounded by the protein matrix and a lipid bilayer envelope. The RNP is composed of the genomic negative sense single-stranded (-ssRNA) that is tightly associated with the N protein (nucleoprotein) and the RNA-dependent RNA polymerase complex (RdRP). The RdRP consists of the L protein subunit (large polymerase subunit), the P protein subunit (phosphoprotein polymerase cofactor), and the M2-1 protein, which acts as a transcription processivity factor. The matrix consists of the M (matrix) protein. The M2-1 protein serves as the bridge between the RNP and the M protein. The matrix supports the viral envelope. The viral envelope contains three embedded viral proteins: fusion protein (F), attachment protein (G), and a small hydrophobic protein (SH). The M protein associates with the cytoplasmic domain of the F protein. The SH protein forms a pentameric ion channel in the viral envelope and is thought to delay apoptosis of infected cells. The assembly and budding of RSV virions primarily occurs at the apical surface of ciliated airway epithelial cells where viral filaments containing RNPs form. The budding of RSV virions requires interactions between viral proteins, host cytoskeletal proteins, and membrane. For review, please refer to Shaikh and Crowe 2013, and Battles and McLellan 2019.&lt;br&gt;&lt;br&gt;Based on the findings that P, M, and F proteins are sufficient for formation of viralâ€‘like particles (VLPs), P protein, particularly its highly phosphorylated serine/threonineâ€‘rich region between amino acids 39 and 57 that likely interacts with M and/or F proteins, may play an important role in the assembly (Meshram and Oomens 2019).
</Comment>
    <BiopaxRef>d9d</BiopaxRef>
    <BiopaxRef>e62</BiopaxRef>
    <BiopaxRef>b5c</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="412.0" CenterY="207.0" Width="500.0" Height="54.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9820962" />
  </DataNode>
  <DataNode TextLabel="RSV-host&#xA;interactions" GraphId="f76e2" Type="Pathway">
    <Comment Source="Reactome">Airway epithelial cells are the primary target for human respiratory syncytial virus (hRSV) and other inhaled pathogens (Zhang et al., 2002). In response to RSV infection, airway epithelial cells initiate both inflammatory responses and antiviral immune responses to effectively eliminate the virus (reviewed by Espinoza, Bueno et al., 2014; Lay et al., 2016; Hu et al., 2020; Ouyang et al., 2022). Pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and retinoic acid-inducible gene-I-like receptors (RLRs), detect viral components such as RSV genomic RNA and trigger the production of pro-inflammatory cytokines, chemokines, and type I interferons (Liu et al. 2007; reviewed by Espinoza et al., 2014; Hu et al., 2020; Ouyang et al., 2022). Additionally, airway epithelial cells recruit other innate immune cells including polymorphonuclear leukocytes (PMNs), macrophages, and natural killer cells to establish an antiviral environment and facilitate the resolution of inflammation within the lungs (Miura 2019). The impact of RSV infection on the host cell transcriptome and proteome is reviewed by Hu et al., 2020. The adaptive immune response controls RSV infection by secreting antibodies (Jones et al., 2018; Fong et al., 2023) or by cytotoxic T lymphocytes (CTLs) that recognize and eliminate RSV-infected cells (Lukens et al., 2010; De et al., 2023). RSV evolved strategies to evade or subvert these host responses, allowing an infection to be established and persist within the host (reviewed by Espinoza, Bohmwald et al., 2014; Lay et al., 2016; Hu et al., 2020; Brasier 2020; Stephens &amp; Varga 2020; Ouyang et al., 2022; van Royen et al., 2022). For example, the NS1 and NS2 proteins target the signaling molecules involved in the innate immune response suppressing PRR-induced IFN production and IFN-mediated signaling pathways (reviewed by Sedeyn et al., 2019; Thornhill &amp; Verhoeven, 2020). Viral SH has been implicated in inhibiting apoptotic pathway, a type of non-inflammatory cell death that limits viral propagation (Li et al., 2015). At the same time, Triantafilou et al. (2013) have reported that viral SH promotes an inflammatory necrotic cell death to release the cell content. Further, the binding of RSV G protein to leukocytes involves the host CX3C chemokine receptor 1 (CX3CR1) and results in blocking signaling and trafficking of CX3CR1-expressing Th1 immune cells to the lungs, facilitating RSV infection (Harcourt et al., 2006). The hRSV NS2 protein induces cell shedding into large airways causing an acute airway obstruction in an animal model of RSV infection through an unknown mechanism (Liesman et al., 2014). &lt;p&gt;Several host factors contribute to the pathogenesis of RSV infection and its long-term effects, including age, prematurity, underlying respiratory conditions such as chronic lung disease including cystic fibrosis, deficiencies in specific immune components or dysregulated immune responses (reviewed by Carvajal et al., 2019). In some cases, an exaggerated immune response to RSV infection can affect the host's ability to control viral infection leading to immunopathology. For example, elevated production of Th2-type cytokines (IL-4, IL-5 and IL-13) in response to RSV infection leads to airway hyperreactivity and increased risk of developing asthma after hRSV infection (Vu et al., 2019; Dong et al., 2023; reviewed by Norlander &amp; Peebles 2020; Manti &amp; Piedimonte 2022). The outcome of RSV infection depends on a complex interplay between the immune responses induced by the host and the strategies developed by RSV to subvert these responses.&lt;p&gt;This Reactome module describes molecular mechanisms by which specific RSV components modulate innate and adaptive immune responses, programmed cell death, and host gene expression.</Comment>
    <BiopaxRef>b7e</BiopaxRef>
    <BiopaxRef>f55</BiopaxRef>
    <BiopaxRef>bf8</BiopaxRef>
    <BiopaxRef>d81</BiopaxRef>
    <BiopaxRef>a75</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="413.0" CenterY="271.0" Width="496.0" Height="50.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9833110" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d9d">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">30723301</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Respiratory syncytial virus entry and how to block it.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Battles MB, McLellan JS.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="df7">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">31117229</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A Contemporary View of Respiratory Syncytial Virus (RSV) Biology and Strain-Specific Differences.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pandya MC, Callahan SM, Savchenko KG, Stobart CC.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cbd">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">36577878</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nirsevimab: First Approval.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Keam SJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ac8">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">36851260</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Jenkins VA, Hoet B, Hochrein H, De Moerlooze L.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d69">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">36851554</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Biochemistry of the Respiratory Syncytial Virus L Protein Embedding RNA Polymerase and Capping Activities.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Sutto-Ortiz P, Eléouët JF, Ferron F, Decroly E.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ce8">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">24362682</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Collins PL, Fearns R, Graham BS.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b75">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">27575793</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fearns R, Deval J.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f4a">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">25683441</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Initiation and regulation of paramyxovirus transcription and replication.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Noton SL, Fearns R.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c95">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11991994</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ada">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">16622022</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lindemans CA, Coffer PJ, Schellens IM, de Graaff PM, Kimpen JL, Koenderman L.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a9b">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28228284</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Zhivaki D, Lemoine S, Lim A, Morva A, Vidalain PO, Schandene L, Casartelli N, Rameix-Welti MA, Hervé PL, Dériaud E, Beitz B, Ripaux-Lefevre M, Miatello J, Lemercier B, Lorin V, Descamps D, Fix J, Eléouët JF, Riffault S, Schwartz O, Porcheray F, Mascart F, Mouquet H, Zhang X, Tissières P, Lo-Man R.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e62">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">23252497</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Molecular mechanisms driving respiratory syncytial virus assembly.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Shaikh FY, Crowe JE.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b5c">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">31009855</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Identification of a human respiratory syncytial virus phosphoprotein domain required for virus-like-particle formation.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Meshram CD, Oomens AGP.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b7e">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">32216549</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Impact of Respiratory Syncytial Virus Infection on Host Functions: Implications for Antiviral Strategies.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hu M, Bogoyevitch MA, Jans DA.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f55">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">26119025</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">New insights on the viral and host factors contributing to the airway pathogenesis caused by the respiratory syncytial virus.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lay MK, Bueno SM, Gálvez N, Riedel CA, Kalergis AM.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bf8">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">36204661</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An overview on the RSV-mediated mechanisms in the onset of non-allergic asthma.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Manti S, Piedimonte G.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d81">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">35216012</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">How RSV Proteins Join Forces to Overcome the Host Innate Immune Response.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Van Royen T, Rossey I, Sedeyn K, Schepens B, Saelens X.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a75">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">25513775</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Modulation of host adaptive immunity by hRSV proteins.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Espinoza JA, Bohmwald K, Céspedes PF, Céspedes PF, Riedel CA, Bueno SM, Kalergis AM.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

